Table 2

Association of plasma IGFBP-2 concentration with the risk of developing type 2 diabetes

Pooled
(n = 2,778, ncases = 755)Men
(n = 1,188, ncases = 444)Women
(n = 1,590, ncases = 311)
HR per SD*95% CIHR per SD95% CIHR per SD95% CI
Model 10.280.24, 0.340.30.24, 0.380.260.19, 0.35
Model 20.410.34, 0.510.410.31, 0.530.420.31, 0.56
Model 30.410.33, 0.50.390.3, 0.520.430.32, 0.57
Model 40.490.4, 0.60.460.35, 0.610.520.4, 0.69
Model 50.560.45, 0.680.470.35, 0.630.70.52, 0.93
Model 60.650.53, 0.80.580.43, 0.770.810.61, 1.07
  • Model 1, adjusted for age and if applicable for sex; model 2, additionally adjusted for waist circumference, prevalence of hypertension, education, physical activity, smoking status, and alcohol intake; model 3: additionally adjusted for IGF-1 and IGFBP-3; model 4: additionally adjusted for FLI; model 5: additionally adjusted for adiponectin, fetuin A, triglycerides, CRP, ALT, γ-GT; model 6: additionally glucose and HbA1c.

  • *HR of developing type 2 diabetes associated with 1 SD higher circulating IGFBP-2 levels.